What is US7803839B2 (and how does it relate to cobimetinib)?
US7803839B2 is a US patent document that (per its title/subject matter in standard patent databases) covers aspects of making or using small-molecule compounds associated with the cobimetinib IP portfolio. Cobimetinib (brand name Cotellic) is a MEK inhibitor developed by Exelixis for oncology uses. The patent number you provided is often surfaced when searching for “cobimetinib synthesis” because it can include chemical-structure claims and example preparation steps that are relevant to how the active pharmaceutical ingredient is manufactured.
If you need the exact synthesis steps tied to this specific patent, you typically have to pull the “Examples” section of the patent text and follow the specific scheme for the particular intermediate/compound recited in the claims.
Where can I find the actual synthesis (example procedures) for US7803839B2?
To get the synthesis details, you need to read the patent’s specification and look for sections labeled like:
- “Examples”
- “Preparation” / “Preparation of [intermediate]”
- reaction schemes tied to named intermediates
- specific reagents/solvents, temperatures, times, and purification steps
Those details are not usually summarized in secondary sources; they are in the patent PDF itself.
How to verify whether the “synthesis” you found actually matches cobimetinib
Patent documents can contain multiple related compounds, intermediates, and analogs. When you’re trying to confirm you’re looking at the cobimetinib route (not a related analog), cross-check:
- the compound name used in the examples
- the chemical structure (or IUPAC name) in the example
- whether the example’s final product matches cobimetinib’s structure
- whether the claims specifically cover cobimetinib (vs. broader classes)
Are there patent-to-manufacturing translations (scale-up, process changes)?
Even when a patent includes example lab-scale synthesis, commercial manufacturing processes often differ (different starting material suppliers, improved reagents, alternative purification steps, solvent swaps, safety/containment changes). Those are usually reflected in later process patents or trade/DMF disclosures rather than in the original “toy” example procedures.
If your goal is to understand feasibility for manufacturing (rather than just identifying the chemistry), you usually look for:
- continuation/divisional patents in the same family
- later process-optimization patents (same active ingredient, improved steps)
- regulatory filings (where available) that disclose manufacturing controls (often not full step-by-step recipes)
Patent landscape and exclusivity signals (possible next search)
If you’re trying to connect this patent to the broader cobimetinib exclusivity and competitor landscape (e.g., who might challenge, when exclusivity ends, what other patents exist in the family), DrugPatentWatch can help identify related patents in the cobimetinib portfolio and their status.
You can start here: https://www.drugpatentwatch.com/ (search “cobimetinib” and then filter to Exelixis portfolio items)
What I need from you to give the exact synthesis route from US7803839B2
Your question is specific (“US7803839B2 cobimetinib exelixis synthesis”), but it doesn’t include the parts you want (full procedure vs. a particular intermediate). If you paste either:
- the “Examples” section text for the relevant preparation, or
- the chemical scheme/example number you care about,
I can rewrite it clearly (reaction-by-reaction) and map which intermediate leads toward cobimetinib.
If you tell me which intermediate/example number in US7803839B2 you want, I’ll focus on that exact synthesis portion.
Sources
- https://www.drugpatentwatch.com/